Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 4
2018 4
2019 1
2020 1
2021 2
2022 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
L’immunothérapie dans les cancers ORL.
Reverdy T, Gau M, Karabajakian A, Neidhardt EM, Fayette J. Reverdy T, et al. Among authors: karabajakian a. Bull Cancer. 2018 Dec;105 Suppl 1:S35-S42. doi: 10.1016/S0007-4551(18)30388-6. Bull Cancer. 2018. PMID: 30595197 Review. French.
Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.
Foy JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, Fekiri D, Robert M, Baffert KA, Hervé G, Quilhot P, Attignon V, Girod A, Chaine A, Benassarou M, Zrounba P, Caux C, Ghiringhelli F, Lantuejoul S, Crozes C, Brochériou I, Pérol M, Fayette J, Bertolus C, Saintigny P. Foy JP, et al. Among authors: karabajakian a. Eur J Cancer. 2022 Oct;174:287-298. doi: 10.1016/j.ejca.2022.06.034. Epub 2022 Aug 26. Eur J Cancer. 2022. PMID: 36038492
Molecular Mechanisms of Kaposi Sarcoma Development.
Karabajakian A, Ray-Coquard I, Blay JY. Karabajakian A, et al. Cancers (Basel). 2022 Apr 7;14(8):1869. doi: 10.3390/cancers14081869. Cancers (Basel). 2022. PMID: 35454776 Free PMC article.
Chemotherapy for recurrent/metastatic head and neck cancers.
Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J. Karabajakian A, et al. Anticancer Drugs. 2017 Apr;28(4):357-361. doi: 10.1097/CAD.0000000000000473. Anticancer Drugs. 2017. PMID: 28166090 Review.
Chemotherapy for localized head and neck squamous cell cancers.
Karabajakian A, Toussaint P, Neidhardt EM, Paulus V, Saintigny P, Fayette J. Karabajakian A, et al. Anticancer Drugs. 2017 Apr;28(4):362-368. doi: 10.1097/CAD.0000000000000480. Anticancer Drugs. 2017. PMID: 28134662 Review.
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
Prasad M, Zorea J, Jagadeeshan S, Shnerb AB, Mathukkada S, Bouaoud J, Michon L, Novoplansky O, Badarni M, Cohen L, Yegodayev KM, Tzadok S, Rotblat B, Brezina L, Mock A, Karabajakian A, Fayette J, Cohen I, Cooks T, Allon I, Dimitstein O, Joshua B, Kong D, Voronov E, Scaltriti M, Carmi Y, Conde-Lopez C, Hess J, Kurth I, Morris LGT, Saintigny P, Elkabets M. Prasad M, et al. Among authors: karabajakian a. J Immunother Cancer. 2022 Mar;10(3):e003917. doi: 10.1136/jitc-2021-003917. J Immunother Cancer. 2022. PMID: 35292516 Free PMC article.
18 results